116640-16-5

Basic information

• Product Name: (S)-tert-butyl 1-hydroxyhexan-2-ylcarbaMate
• Synonyms: (S)-tert-butyl 1-hydroxyhexan-2-ylcarbaMate
• CAS NO: 116640-16-5
• Molecular Formula: C₁₁H₂₃NO₃
• Molecular Weight: 217.30522
• Mol File: 116640-16-5.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-tert-butyl 1-hydroxyhexan-2-ylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 1-hydroxyhexan-2-ylcarbaMate(116640-16-5)
• EPA Substance Registry System: (S)-tert-butyl 1-hydroxyhexan-2-ylcarbaMate(116640-16-5)

Safety Data

• Hazardous Substances Data: 116640-16-5(Hazardous Substances Data)

Usage

General Description

(S)-tert-butyl 1-hydroxyhexan-2-ylcarbamate, also known as talsaclidine, is a chemical compound with the molecular formula C12H25NO3. It is a highly selective M1 muscarinic receptor agonist and has been studied for its potential use in the treatment of cognitive disorders such as Alzheimer's disease and schizophrenia. Talsaclidine has been shown to improve cognitive function and has neuroprotective effects in animal models. It is also being investigated for its potential to treat other neurological and psychiatric disorders. Additionally, talsaclidine has shown promise in preclinical studies for its ability to enhance memory and learning processes.

Upstream product

• 335628-17-6 (4S,5R)-3-tert-butoxycarbonyl-4-butyl-5-methoxy-2-oxazolidinone 
• 6404-28-0 Boc-Nle-OH 
• 24424-99-5 di-tert-butyl dicarbonate 
• 80696-29-3 (S)-(+)-2-Amino-1-hexanol 
• 116611-53-1 [(R)-2-Benzenesulfonyl-1-(tetrahydro-pyran-2-yloxymethyl)-pentyl]-carbamic acid tert-butyl ester 
• 116611-44-0 ((R)-2-benzenesulfonyl-1-hydroxymethyl-ethyl)carbamic acid tert-butyl ester 
• 116611-43-9 (R)-2-tert-butyl carbamoyl-1-hydroxy-3-(phenylthio)propane 
• 116611-42-8 (R)-2-tert-butoxycarbonylamino-3-phenylsulfanylpropionic acid methyl ester 
• 116611-45-1 (2R)-2-t-butoxycarbonylamino-3-phenylsulfonyl-1-(2-tetrahydropyranyloxy)propane 
• 56926-94-4 methyl (2S)-2-[N-(t-butoxycarbonyl)amino]-3-(4-methylbenzenesulfonyl)-oxypropionate 
• 2766-43-0 N-tert-butyloxycarbonyl-L-serine methyl ester 
• 335627-74-2 (4S,5R)-4-butyl-5-methoxy-2-oxazolidinone 
• 327-57-1 L-Norleucine 
• 87974-77-4 methyl (2S)-2-tert-butoxycarbonylaminohexanoate 

Downstream Products

• 6404-28-0 Boc-Nle-OH 
• 951035-66-8 (S,Z)-tert-butyl 1-phenyloct-2-en-4-ylcarbamate 
• 951035-67-9 2-hydroxy-N-((S)-1-phenyloctan-4-yl)pentadecanamide 
• 951035-68-0 2-hydroxy-N-((S)-1-phenyloctan-4-yl)hexadecanamide 
• 865537-92-4 2-[(S)-2-(1-Benzyl-propoxycarbonylamino)-1-hydroxy-hexyl]-thiazole-4-carboxylic acid ethyl ester 
• 865537-90-2 2-[(S)-2-(1-Benzyl-2-methyl-propoxycarbonylamino)-1-hydroxy-hexyl]-thiazole-4-carboxylic acid ethyl ester 
• 865537-95-7 2-[(S)-2-(1-Benzyl-3-methyl-butoxycarbonylamino)-1-hydroxy-hexyl]-thiazole-4-carboxylic acid ethyl ester 
• 865537-85-5 2-[(S)-2-((S)-2-Cyclohexyl-1-methyl-ethoxycarbonylamino)-1-hydroxy-hexyl]-thiazole-4-carboxylic acid ethyl ester 
• 1616273-52-9 C₁₁H₂₃NO₂S 
• 1606171-51-0 (S)-2-aminohexane-1-thiol trifluoroacetate salt 
• 600143-18-8 benzyl (E,4S)-4-[(2-hydroxydodecanoyl)amino]oct-2-enoate 
• 600143-16-6 benzyl (E,4S)-4-[(tert-butoxycarbonyl)amino]oct-2-enoate 
• 757976-41-3 N¹-(4-methoxy-phenyl)-hexane-1,2-diamine 

Relevant articles and documents

Structural Basis for α-Helix Mimicry and Inhibition of Protein–Protein Interactions with Oligourea Foldamers

Efficient optimization of a peptide lead into a drug candidate frequently needs further transformation to augment properties such as bioavailability. Among the different options, foldamers, which are sequence-based oligomers with precise folded conformation, have emerged as a promising technology. We introduce oligourea foldamers to reduce the peptide character of inhibitors of protein–protein interactions (PPI). However, the precise design of such mimics is currently limited by the lack of structural information on how these foldamers adapt to protein surfaces. We report a collection of X-ray structures of peptide–oligourea hybrids in complex with ubiquitin ligase MDM2 and vitamin D receptor and show how such hybrid oligomers can be designed to bind with high affinity to protein targets. This work should enable the generation of more effective foldamer-based disruptors of PPIs in the context of peptide lead optimization.

COMPOUNDS AND METHOD OF USE

This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.

Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: α-Branched quaternary amines

We report the synthesis and biological evaluation of a series of novel α-branched pyrazinoyl quaternary amines for their ability to block ion transport via the epithelial sodium channel (ENaC) in human bronchial epithelial cells (HBECs). Compound 12g has an IC50 of 30 nM and is highly efficacious in the Guinea-pig tracheal potential difference (TPD) model of ENaC blockade with an ED50 of 1 μg kg-1 at 1 h. In addition the SAR results demonstrate for the first time the chiral nature of the binding site of human ENaC. As such, pyrazinoyl quaternary amines represent a promising new class of ENaC blockers for the treatment of cystic fibrosis that are structurally distinct from the pyrazinoyl guanidine chemotype found in prototypical ENaC blockers such as amiloride.